Navigation Links
Xceed Molecular Names Fran Tuttle to Its Board of Trustees
Date:10/9/2007

WELLESLEY, Mass., Oct. 9 /PRNewswire/ -- Xceed Molecular Corporation, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced today that Fran Tuttle has been appointed to Xceed's board of directors. Ms. Tuttle is president and chief executive officer of HX Diagnostics, a California-based company focused on developing a point-of-care diagnostic for avian flu.

"Fran is the ideal complement to our board," said Xceed's President and CEO, David Deems. "She has more than 20 years of leadership in the diagnostics industry -- including significant experience with commercialization of novel technologies. Her knowledge, counsel, and close connections with thought leaders in the field will be invaluable to us as we continue to further develop our products and solutions for multiplexed gene-expression tests for clinical research today, and in vitro diagnostics tomorrow."

Prior to HX Diagnostics, Ms. Tuttle was president and chief executive officer of Protedyne Corporation (now part of LabCorp), which developed robotics for the molecular-diagnostic-testing industry. Previously, she was senior vice president of near patient testing at Bayer Diagnostics, one of the world's largest diagnostic companies. At Bayer, she was responsible for a worldwide business of $400 million. Before joining Bayer Diagnostics, she spent 20 years at Chiron Diagnostics (formerly Ciba Corning Diagnostics), a leader in molecular and immunodiagnostics. Ms. Tuttle began her career as a CPA at Peat, Marwick, Mitchell and Company (now KPMG). She holds a master's in business administration from Harvard Business School as well as bachelor's degrees in accounting from the University of North Carolina at Chapel Hill and German from Duke University.

About Xceed Molecular

Xceed's vision is to advance molecular diagnostics and improve health outcomes by providing a cost-effective, automated system and services that facilitate the rapid translation of novel multiplexed genomic tests from research into routine clinical use. We designed our proprietary system to perform multiplexed molecular assays with superior accuracy, reproducibility, speed, and scalability at significantly lower cost than conventional array- or PCR-based systems. Our offerings include: the Ziplex(TM) System for automated gene-expression analysis, comprising an automated workstation, TipChip consumable arrays, and reagents (available in the US and Canada for research use only); Signature Chips -- pre-configured arrays focusing on a number of specific disease targets; and custom array services. Xceed's R&D and manufacturing operations are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit http://www.Xceedmolecular.com.


'/>"/>
SOURCE Xceed Molecular Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AIDS toll set to exceed Black Death
2. America’s Demand For Organic Foods Far Exceeds the Suppl
3. Mercury Levels In Canned Tuna Exceed Guidelines
4. Cholesterol in Stroke Patients Exceeds National Guidelines
5. Dengue Deaths in Cambodia This Year Exceed 2006 Toll
6. Molecular markers for early diagnosis of breast and ovarian cancer
7. Scientists Developed Map For Brain Molecular Communities
8. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
9. Molecular Flaw Detected in Aggressive Breast Cancers
10. Molecular Computer Developed To perform Calculations From Within Human Body
11. Lung cancer molecular profile discovered by researchers.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... The Pharmacy and Medically Underserved ... bipartisan original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The ... Chain Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their ...
(Date:1/24/2017)... ... 23, 2017 , ... The TouchPoint Solution, parent company of ... into the product’s app. The data replicates and validates Co-Founder and Neuropsychologist ... 30 seconds of using Buzzies, people experienced a 74 percent reduction in their ...
(Date:1/23/2017)... York, NY (PRWEB) , ... January 23, 2017 , ... ... announced today that John J. Nelson, a senior accountant at the Firm, will participate ... of Make-A-Wish® Hudson Valley. Over 200 runners will race up 1,576 steps, a vertical ...
(Date:1/23/2017)... FL (PRWEB) , ... January 23, 2017 , ... Wooden and plastic balance boards have ... strength and improve balance. Kumo Board is the first and only balance board ... it to be soft and rigid at the same time as well as skill-level adjustable ...
(Date:1/23/2017)... ... 2017 , ... METTLER TOLEDO has announced the availability of ... PAT Tools . , Crystallization is a common step used during ... Chemists now spend more time developing better intermediate and final crystallization steps. ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... YORK , Jan. 23, 2017 ... detect, and control light. The interaction of these ... used in a wide range of applications. These ... aerospace and defense, telecommunications, and healthcare among others. ... primarily owing to its low power consumption, reliability, ...
(Date:1/24/2017)... VALLEY COTTAGE, New York , January 23, 2017 ... Projected to Witness Sluggish Growth ... world are derived from formulating Active Pharmaceutical Ingredients (API), ... isopropanol, propanol and propylene glycol. Production of ... Asia-Pacific excluding Japan ...
(Date:1/23/2017)... 2017  Therabron Therapeutics, Inc., a clinical-stage biotechnology ... respiratory care, today announced that the European Medicines ... granted Orphan Drug Designation for Therabron,s CG367 program, ... (BOS).  "We are pleased to have ... treat patients diagnosed with BOS following lung transplantation. ...
Breaking Medicine Technology: